Violations at Novo’s Indiana Plant ‘Unacceptable,’ FDA Says
Slapped with the most severe post-inspection classification, the state of Novo Nordisk’s Indiana manufacturing site could pose a problem for clients, including Regeneron and Scholar Rock.
Violations at Novo’s Indiana Plant ‘Unacceptable,’ FDA Says Read More »
